MedTrace Logo

Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers

NCT04304547 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-08-13

No results posted yet for this study

Summary

Phase I clinical trial to compare the pharmacokinetics and safety of CKD-348 with co-administration of CKD-828, D097 and D337 in healthy adult volunteers

Conditions

  • Healthy

Interventions

DRUG

CKD-828, D097, D337, CKD-348 T1, CKD-348 T2

Subject of sequence A takes IP in the following order: 1. Each tablet of CKD-828 and D097 and D337 be taken at once 2. CKD-348 T1 1 tablet 3. CKD-348 T2 1 tabet

DRUG

CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,

Subject of sequence B takes IP in the following order: 1. CKD-348 T1 1 tablet 2. CKD-348 T2 1 tablet 3. Each tablet of CKD-828 and D097 and D337 be taken at once

DRUG

CKD-348 T2, CKD-348 T1, CKD-828, D097, D337

Subject of sequence C takes IP in the following order: 1. CKD-348 T2 1 tablet 2. Each tablet of CKD-828 and D097 and D337 be taken at once 3. CKD-348 T1 1 tablet

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Jae Yong Chung · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-04
Primary Completion
2020-04-02
Completion
2020-04-02

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04304547 on ClinicalTrials.gov